CA2085421A1 - Pharmaceutical composition for the inhibition of bone resorption - Google Patents

Pharmaceutical composition for the inhibition of bone resorption

Info

Publication number
CA2085421A1
CA2085421A1 CA002085421A CA2085421A CA2085421A1 CA 2085421 A1 CA2085421 A1 CA 2085421A1 CA 002085421 A CA002085421 A CA 002085421A CA 2085421 A CA2085421 A CA 2085421A CA 2085421 A1 CA2085421 A1 CA 2085421A1
Authority
CA
Canada
Prior art keywords
denotes
group
compound
bone
pth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002085421A
Other languages
English (en)
French (fr)
Inventor
Mizuho Inazu
Ryoichi Satoh
Tsutomu Inoue
Hiroshi Kitagawa
Masakazu Katoh
Heinrich Englert
Denis Carniato
Hans-Jochen Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2085421A1 publication Critical patent/CA2085421A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002085421A 1991-12-16 1992-12-15 Pharmaceutical composition for the inhibition of bone resorption Abandoned CA2085421A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP3-331,767 1991-12-16
JP33176791 1991-12-16
JP4-239,144 1992-09-08
JP23914492A JP3502403B2 (ja) 1991-12-16 1992-09-08 骨吸収抑制剤

Publications (1)

Publication Number Publication Date
CA2085421A1 true CA2085421A1 (en) 1993-06-17

Family

ID=26534099

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002085421A Abandoned CA2085421A1 (en) 1991-12-16 1992-12-15 Pharmaceutical composition for the inhibition of bone resorption

Country Status (10)

Country Link
US (1) US5317029A (enExample)
EP (1) EP0547545B1 (enExample)
JP (1) JP3502403B2 (enExample)
KR (1) KR100257496B1 (enExample)
AT (1) ATE114465T1 (enExample)
CA (1) CA2085421A1 (enExample)
DE (1) DE69200757T2 (enExample)
DK (1) DK0547545T3 (enExample)
ES (1) ES2066546T3 (enExample)
TW (1) TW223016B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
US5389646A (en) * 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
GB9408577D0 (en) * 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
US5629429A (en) * 1995-06-07 1997-05-13 Bristol-Myers Squibb Company Process for preparing 4-arylamino-benzopyran and related compounds
US5612323A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phosphinic ester substituted benzopyran derivatives
US5612370A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
WO2004028444A2 (en) * 1999-06-02 2004-04-08 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
KR100389127B1 (ko) * 2000-10-09 2003-06-25 동부한농화학 주식회사 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
TWI396543B (zh) 2005-05-12 2013-05-21 Sankyo Co 取代丙烯醯胺衍生物及含有它之醫藥組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZM7682A1 (en) * 1981-09-25 1983-05-23 Beecham Group Plc Active compounds
DE3364145D1 (de) * 1982-04-08 1986-07-24 Beecham Group Plc Antihypertensive benzopyranols
JPS58219183A (ja) * 1982-04-28 1983-12-20 ビ−チヤム・グル−プ・ピ−エルシ− 新規なクロマノ−ル，その製法及びそれらを含む製薬組成物
EP0093535B1 (en) * 1982-04-28 1986-12-30 Beecham Group Plc Novel chromenes and chromans
GB8513369D0 (en) * 1985-05-28 1985-07-03 Beecham Group Plc Treatment
DE3703227A1 (de) * 1987-02-04 1988-08-18 Hoechst Ag Substituierte 3,4-dihydro-2h-benzopyrane, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
DE3823533A1 (de) * 1988-07-12 1990-02-08 Beiersdorf Ag Substituierte 4-heterocyclyl-2h-benzo(b)pyrane, verfahren und 4-hydroxy-3-brom-, 3,4-oxiranyl-3,4-dehydro-2h-benzo(b)pyrane als zwischenprodukte zu ihrer herstellung, sowie sie enthaltende pharmazeutsche praeparate

Also Published As

Publication number Publication date
DE69200757T2 (de) 1995-05-11
ES2066546T3 (es) 1995-03-01
KR930012036A (ko) 1993-07-20
EP0547545B1 (en) 1994-11-30
JPH05221860A (ja) 1993-08-31
DE69200757D1 (de) 1995-01-12
DK0547545T3 (da) 1995-05-15
ATE114465T1 (de) 1994-12-15
JP3502403B2 (ja) 2004-03-02
TW223016B (enExample) 1994-05-01
EP0547545A1 (en) 1993-06-23
US5317029A (en) 1994-05-31
KR100257496B1 (ko) 2000-08-01

Similar Documents

Publication Publication Date Title
AU747407B2 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections
US6174857B1 (en) Composition and method for the treatment of osteoporosis in mammals
Holmberg et al. Genetic variants of von Willebrand's disease
KR100638684B1 (ko) 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
EP0547545B1 (en) Pharmaceutical composition for the inhibition of bone resorption
JPH10504574A (ja) 静脈内注入用アレンドロナート組成物
JPS63239291A (ja) 新規ヘテロ環置換ジホスホネート化合物、医薬組成物並びにカルシウム及びリン酸代謝異常の治療方法
IE64949B1 (en) Suppression of parathyroid hormone synthesis and secretion
Saha et al. Pharmacokinetics of clodronate in renal failure
JP2568999B2 (ja) ｇｅｍ−ジホスホネ−トを含有する薬学的組成物
MXPA01006473A (es) Uso de bisfonatos para la profilaxis y el tratamiento de procesos infecciosos.
Bansil et al. Serum soluble interleukin‐2 receptor levels in chronic progressive, stable and steroid‐treated multiple sclerosis
Rico et al. Treatment of multiple myeloma with nasal spray calcitonin: a histomorphometric and biochemical study
WO2004110458A1 (en) Phenothiazine enantiomers as agents for the prevention of bone loss
CA2794581A1 (en) Method of treating osteoporosis
Light et al. Urinary ionized calcium in urolithiasis Effect of cranberry juice
Azima et al. Alteration of copper metabolism in chlorpromazine-treated cases
CA1321354C (en) Use of c-5 mono-substituted barbiturates to treat disorders of uric acid metabolism
Mertz et al. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
JPS59110621A (ja) 利尿剤
Bäck et al. Accidental doxorubicin overdosage
JPH06183958A (ja) 骨疾患の予防・治療剤
JP5078124B2 (ja) ヒト破骨細胞形成抑制活性を有する新規のペプチド
Schlake et al. Acute systemic vanadate poisoning presenting as cerebrovascular ischemia with prolonged reversible neurological deficits (PRIND)
Levine et al. Hypercalcemia: pathophysiology and treatment

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued